89Bio Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters11-06

* 89Bio Inc is expected to show a rise in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024

* The San Francisco California-based company is expected to report revenue of $535.71 thousand, according to the mean estimate from 7 analysts, based on LSEG data.

* LSEG's mean analyst estimate for 89Bio Inc is for a loss of 64 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for 89Bio Inc is $29.50, above its last closing price of $9.23.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.57 -0.57 -0.48 Beat 15.8

Mar. 31 2024 -0.46 -0.46 -0.54 Missed -17.1

Jan. 1 0001 -0.48 -0.49 -0.50 Missed -1

Sep. 30 2023 -0.53 -0.53 -0.45 Beat 15.1

Jun. -0.42 -0.41 -0.52 Missed -26.4

30 2023

Mar. 31 2023 -0.48 -0.52 -0.54 Missed -3.5

Jan. 1 0001 -0.68 -0.69 -0.48 Beat 30.1

Sep. 30 2022 -0.82 -0.80 -0.57 Beat 28.5

This summary was machine generated November 6 at 04:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481192206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 12:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481192206","market":"us","top_or_hot":-1,"title":"89Bio Inc    expected to post a loss of 64 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* 89Bio Inc     is expected to show a rise in quarterly revenue when it reports  results on November 7 (estimated) for the period ending September 30 2024</p><p>   * The San Francisco California-based  company is expected to report revenue of $535.71 thousand, according to the mean estimate from 7 analysts, based on LSEG data.</p><p>   * LSEG's mean analyst estimate for 89Bio Inc is for a loss of 64 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for 89Bio Inc is $29.50, above its last closing price of $9.23. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.57       -0.57      -0.48     Beat    15.8</p><p>Mar. 31 2024  -0.46       -0.46      -0.54     Missed  -17.1</p><p>Jan. 1 0001   -0.48       -0.49      -0.50     Missed  -1</p><p>Sep. 30 2023  -0.53       -0.53      -0.45     Beat    15.1</p><p>Jun.        -0.42       -0.41      -0.52     Missed  -26.4</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.48       -0.52      -0.54     Missed  -3.5</p><p>Jan. 1 0001   -0.68       -0.69      -0.48     Beat    30.1</p><p>Sep. 30 2022  -0.82       -0.80      -0.57     Beat    28.5</p><p>This summary was machine generated November 6 at 04:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>89Bio Inc    expected to post a loss of 64 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n89Bio Inc    expected to post a loss of 64 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 12:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* 89Bio Inc     is expected to show a rise in quarterly revenue when it reports  results on November 7 (estimated) for the period ending September 30 2024   * The San Francisco California-based  ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ETNB","symbol_name":"89Bio, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481192206","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481192206","pubTimestamp":1730867634,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* 89Bio Inc     is expected to show a rise in quarterly revenue when it reports  results on November 7 (estimated) for the period ending September 30 2024   * The San Francisco California-based  compa","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ETNB":"89Bio, Inc."},"translate_title":"89Bio Inc预计每股亏损64美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ETNB":0.9},"content_text":"* 89Bio Inc     is expected to show a rise in quarterly revenue when it reports  results on November 7 (estimated) for the period ending September 30 2024   * The San Francisco California-based  company is expected to report revenue of $535.71 thousand, according to the mean estimate from 7 analysts, based on LSEG data.   * LSEG's mean analyst estimate for 89Bio Inc is for a loss of 64 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" 2 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for 89Bio Inc is $29.50, above its last closing price of $9.23. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -0.57       -0.57      -0.48     Beat    15.8Mar. 31 2024  -0.46       -0.46      -0.54     Missed  -17.1Jan. 1 0001   -0.48       -0.49      -0.50     Missed  -1Sep. 30 2023  -0.53       -0.53      -0.45     Beat    15.1Jun.        -0.42       -0.41      -0.52     Missed  -26.430 2023                                                Mar. 31 2023  -0.48       -0.52      -0.54     Missed  -3.5Jan. 1 0001   -0.68       -0.69      -0.48     Beat    30.1Sep. 30 2022  -0.82       -0.80      -0.57     Beat    28.5This summary was machine generated November 6 at 04:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481192206"}